Berberine · BBR · Berberine Hydrochloride
Natural insulin sensitizer that compounds GLP-1 metabolic outcomes.
FDA
Approved
WADA
Not Listed
HALF-LIFE
~4–5 hours
ROUTE
Oral
SCHEDULE
3× daily with meals
In Plain English
Natural insulin sensitizer that compounds GLP-1 metabolic outcomes.
Status & Legality
What do these mean?Insulin sensitization
Blood glucose control
GLP-1 metabolic synergy
Lipid management
Berberine activates AMPK (the same pathway as metformin) and improves insulin receptor sensitivity. Multiple RCTs show it lowers HbA1c, fasting glucose, and LDL-C comparably to first-line medications. Combined with GLP-1 peptides, berberine provides a complementary mechanism — GLP-1 slows gastric emptying and reduces appetite while berberine improves peripheral insulin sensitivity, producing additive metabolic improvements.
GI upset, diarrhea, nausea — common initially, resolves in 2–4 weeks
Constipation in some users
Hypoglycemia risk with insulin or sulfonylureas
CYP450 inhibition — check drug interactions
Taking all at once instead of spreading 3× daily — the short half-life (~4 hours) requires split dosing for consistent blood levels and efficacy
Not warning about hypoglycemia risk when combining with insulin or sulfonylureas — the additive glucose-lowering effect is clinically significant
Starting at full dose immediately — GI side effects are common the first 2–4 weeks; begin at 500 mg once daily and titrate up
Metformin — additive AMPK effects; hypoglycemia risk when combined; monitor glucose and consider reducing metformin
Insulin and sulfonylureas — significant hypoglycemia risk; reduce doses when adding berberine
CYP450 substrates — berberine inhibits CYP2D6 and CYP3A4; check drug interactions for any CYP-metabolized medications
Berberine's glucose-lowering effect is comparable to metformin in multiple RCTs — this is not typical supplement-grade evidence. The CYP450 drug interactions are the most important safety consideration; check your full medication list. Combined with GLP-1 agonists, the additive metabolic improvement is real and meaningful, but so is the hypoglycemia risk.
SEMAGLUTIDE
FDA-approved GLP-1 agonist — weight loss and blood sugar control.
TIRZEPATIDE
Dual GIP/GLP-1 agonist — superior weight loss to semaglutide.
RETATRUTIDE
Triple agonist (GLP-1/GIP/Glucagon) — next-gen weight loss.
Free, no account needed
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepvault.us to opt out any time.
Stats
Sources & Studies
Dong H. et al., Evid Based Complement Alternat Med, 2012